Predictive and prognostic factors in small cell lung carcinoma (SCLC) - Analysis from routine clinical practice

Anticancer Research

Volumn 26, Issue 6 C, 2006, Pages 4825-4832

  Brueckl, Wolfgang M ^a,b   Herbst, Lara ^a   Lechler, Annette ^a   Fuchs, Florian ^a   Schoeberl, Anja ^a   Zirlik, Sabine ^a   Klein, Peter ^a   Brunner, Thomas B ^a   Papadopoulos, Thomas ^a   Hohenberger, Werner ^a   Hahn, Eckhart G ^a   Wiest, Gunther H ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Department of Internal Medicine 1 ^*  (Germany)

Author keywords

Prognostic factor; Response prediction; Small cell lung cancer (SCLC)

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; FEMALE; FEVER; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; LEUKOPENIA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; PRIORITY JOURNAL; PROGNOSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 33845938337     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E and Minna JD: Small cell lung cancer 1973-1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys 10: 515-539, 1984.
2. Aisner J, Whitacre M, VanEcho DA, Wesley M and Wiernik PH: Doxorubicin, Cyclophosphamide and VP16-213 (ACE) in the treatment of small cell lung cancer. Cancer Chemother Pharmacol 7: 187-193, 1982.
3. Tjan-Heijnen VC, Caleo S, Postmus PE, Ardizzoni A, Burghouts JT, Buccholz E, Biesma B, Gorlia T, Crott R, Giaccone G, Debruyne C and Manegold C: Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923). Ann Oncol 14: 248-257, 2003.
4. Souhami RL, Bradbury I, Geddes DM, Spiro SG, Harper PG and Tobias JS: Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung. Cancer Res 45: 2878-2882, 1985.
5. Wolf M, Holle R, Hans K, Drings P and Havemann K: Analysis of prognostic factors in 766 patients with small cell lung cancer (SCLC): the role of sex as a predictor for survival. Br J Cancer 63: 986-992, 1991.
6. Chute JP, Venzon DJ, Hankins L, Okunieff P, Frame JN, Ihde DC and Johnson BE: Outcome of patients with small-cell lung cancer during 20 years of clinical research at the US National Cancer Institute. Mayo Clin Proc 72: 901-912, 1997.
7. Osterlind K and Andersen PK: Prognostic factors in small cell lung cancer: multivariate model based on 778 patients treated with chemotherapy with or without irradiation. Cancer Res 46: 4189-4194, 1986.
8. Bremnes RM, Sundstrom S, Aasebo U, Kaasa S, Hatlevoll R and Aamdal S: The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 39: 303-313, 2003.
9. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, Bureau G, Dabouis G, Van Cutsem O, Mommen P, Ninane V and Klastersky J: Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer 89: 523-533, 2000.
10. Sagman U, Feld R, Evans WK, Warr D, Shepherd FA, Payne D, Pringle J, Yeoh J, DeBoer G and Malkin A: The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer. J Clin Oncol 9: 954-961, 1991.
11. Albain KS, Crowley JJ, LeBlanc M and Livingston RB: Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 8: 1563-1574, 1990.
12. Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian AP, Comis R, Eaton W, Zimmer B and Green M: Prognostic factors in small-cell carcinoma of the lung: an analysis of 1,521 patients. J Clin Oncol 7: 344-354, 1989.
13. Christodoulou C, Pavlidis N, Samantas E, Fountzilas G, Kouvatseas G, Pagdatoglou K, Palamidas F, Nikolaidis C, Angelidou M, Kalofonos HP, Kosmidis P and Skarlos DV: Prognostic factors in Greek patients with small-cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group Study. Anticancer Res 22: 3749-3758, 2002.
14. Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J and Verweij J: Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 75: 2090-2096, 1997.
15. Brock MV, Hooker CM, Syphard JE, Westra W, Xu L, Alberg AJ, Mason D, Baylin SB, Herman JG, Yung RC, Brahmer J, Rudin CM, Ettinger DS and Yang SC: Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg 129: 64-72, 2005.
16. Johnson DH, Einhorn LH, Birch R, Vollmer R, Perez C, Krauss S, Omura G and Greco FA: A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 5: 1731-1738, 1987.
17. Arriagada R, Le Chevalier T, Pignon JP, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M and Ruffie P: Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 329: 1848-1852, 1993.
18. Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M and Phares JC: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12: 2022-2034, 1994.
19. Humblet Y, Weynants P, Bosly A, Majois F, Duprez P, Francis C, Beauduin M, Machiels J, Gailly C and Delaunois L: Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: a dose escalation study of carboplatin. UCL Clinical Oncology Group. Med Oncol Tumor Pharmacother 6: 207-212, 1989.
20. Tjan-Heijnen VC, Wagener DJ and Postmus PE: An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn. Ann Oncol 13: 1519-1530, 2002.
21. Byhardt RW, Hartz A, Libnoch JA, Hansen R and Cox JD: Prognostic influence of TNM staging and LDH levels in small cell carcinoma of the lung (SCCL). Int J Radiat Oncol Biol Phys 12: 771-777, 1986.
22. Ganz PA, Ma PY, Wang HJ and Elashoff RM: Evaluation of three biochemical markers for serially monitoring the therapy of small-cell lung cancer. J Clin Oncol 5: 472-479, 1987.
23. Ando S, Suzuki M, Yamamoto N, Iida T and Kimura H: The prognostic value of both neuron-specific enolase (NSE) and Cyfra21-1 in small cell lung cancer. Anticancer Res 24: 1941-1946, 2004.
24. Molina R, Auge JM, Filella X, Vinolas N, Alicarte J, Domingo JM and Ballesta AM: Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. Anticancer Res 25: 1773-1778, 2005.